Barrington SE, et al. - Via a subsidiary analysis of the RAPID trial, researchers examined the prognostic significance of pretreatment risk factors and positron emission tomography (PET) score in determining outcomes in Hodgkin lymphoma (HL). Following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine, PET assessment was done on patients with stage IA to IIA HL and no mediastinal bulk. A fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field radiotherapy were provided to 143 PET-positive patients (PET score, 3 to 5), and involved-field radiotherapy (n=208) or no additional treatment (n=211) were provided to 419 patients in complete metabolic remission. Before and after adjustment for baseline risk stratification, high PET score was noted to be correlated with inferior event-free survival. As per outcomes, the prognostic ability of a positive PET scan was not uniform in RAPID; only a PET score of 5 (uptake ≥ three times maximum liver uptake) was correlated with inferior outcomes.